Chiara Terracciano

List of Publications by Year
in descending order

52	1,655	304368	301761
papers	citations	22 h-index	39 g-index

53	53	53	5756
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach. Neurology International, 2022, 14, 368-377.	1.3	5
2	Diagnostic Accuracy of a Bedside Screening Tool for Dysphagia (BSTD) in Acute Stroke Patients. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105470.	0.7	6
3	Novel autophagic vacuolar myopathies: Phenotype and genotype features. Neuropathology and Applied Neurobiology, 2021, 47, 664-678.	1.8	4
4	Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families. International Journal of Molecular Sciences, 2021, 22, 3625.	1.8	2
5	Diagnostic Accuracy of Dysphagia Screening in Stroke Care: Answer to the Letter by Toscano etÂal.. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105666.	0.7	0
6	Quantitative Evaluation of Upright Posture by x-Ray and 3D Stereophotogrammetry with a New Marker Set Protocol in Late Onset Pompe Disease. Journal of Neuromuscular Diseases, 2021, 8, 979-988.	1.1	6
7	Intrafamilial â€œDOAâ€plusâ€•phenotype variability related to different OMI/HTRA2 expression. American Journal of Medical Genetics, Part A, 2020, 182, 176-182.	0.7	2
8	COVID-19-Related Stroke: Barking up the Wrong Tree?. European Neurology, 2020, 83, 218-219.	0.6	5
9	Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clinica Chimica Acta, 2020, 509, 135-138.	0.5	168
10	Stroke in COVID-19 patientsâ€”A case series from Italy. International Journal of Stroke, 2020, 15, 701-702.	2.9	21
11	The Baffling Case of Ischemic Stroke Disappearance from the Casualty Department in the COVID-19 Era. European Neurology, 2020, 83, 213-215.	0.6	168
12	The Autophagy Signaling Pathway: A Potential Multifunctional Therapeutic Target of Curcumin in Neurological and Neuromuscular Diseases. Nutrients, 2019, 11, 1881.	1.7	35
13	Potential of Curcumin in Skin Disorders. Nutrients, 2019, 11, 2169.	1.7	106
14	Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity. Journal of Neurology, 2019, 266, 982-989.	1.8	14
15	Late adult-onset adrenomyeloneuropathy evolving with atypical severe frontal lobe syndrome: Importance of neuroimaging. Radiology Case Reports, 2019, 14, 309-314.	0.2	2
16	Nodular morphea in a patient with Steinert disease. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 209-210.	0.8	0
17	Successful long-term therapy with flecainide in a family with paramyotonia congenita. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1232-1234.	0.9	7
18	Neurofibromatous neuropathy: An ultrastructural study. Ultrastructural Pathology, 2018, 42, 312-316.	0.4	3

#	Article	IF	Citations
19	Aquaporin 4 expression in human skeletal muscle fiber types. Muscle and Nerve, 2018, 57, 856-858.	1.0	4
20	Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy. Journal of Cellular Physiology, 2018, 233, 5829-5837.	2.0	15
21	Validation of the Nine Hole Peg Test as a measure of dexterity in myotonic dystrophy type 1. Neuromuscular Disorders, 2018, 28, 947-951.	0.3	5
22	Cutaneous features of myotonic dystrophy types 1 and 2: Implication of premature aging and vitamin D homeostasis. Neuromuscular Disorders, 2017, 27, 163-169.	0.3	18
23	LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310164.	0.9	50
24	Neutral lipidâ€storage disease with myopathy and extended phenotype with novel PNPLA2 mutation. Muscle and Nerve, 2016, 53, 644-648.	1.0	11
25	Neuromuscular transmission abnormalities in myotonic dystrophy type 1: A neurophysiological study. Clinical Neurology and Neurosurgery, 2016, 150, 84-88.	0.6	6
26	Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors. Journal of Neurology, 2016, 263, 492-498.	1.8	32
27	An Age-Standardized Prevalence Estimate and a Sex and Age Distribution of Myotonic Dystrophy Types 1 and 2 in the Rome Province, Italy. Neuroepidemiology, 2016, 46, 191-197.	1.1	37
28	ALS5/SPG11/KIAA1840mutations cause autosomal recessive axonal Charcotâ€“Marieâ€“Tooth disease. Brain, 2016, 139, 73-85.	3.7	80
29	Impaired healing of fragility fractures in type 2 diabetes: clinical and radiographic assessments and serum cytokine levels. Aging Clinical and Experimental Research, 2015, 27, 37-44.	1.4	17
30	Complete loss of the DNAJB6 G/F domain and novel missense mutations cause distal-onset DNAJB6 myopathy. Acta Neuropathologica Communications, 2015, 3, 44.	2.4	45
31	Auto-reactions, autoimmunity and psoriatic arthritis. Autoimmunity Reviews, 2015, 14, 1142-1146.	2.5	47
32	Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and selfâ€reported questionnaires. European Journal of Neurology, 2014, 21, 929-934.	1.7	37
33	Sleep disorders in spinal and bulbar muscular atrophy (Kennedyâ€™s disease): a controlled polysomnographic and self-reported questionnaires study. Journal of Neurology, 2014, 261, 889-893.	1.8	21
34	Differential features of muscle fiber atrophy in osteoporosis and osteoarthritis. Osteoporosis International, 2013, 24, 1095-1100.	1.3	53
35	Vitamin D deficiency in myotonic dystrophy type 1. Journal of Neurology, 2013, 260, 2330-2334.	1.8	24
36	Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology, 2012, 79, 1182-1184.	1.5	27

#	Article	IF	Citations
37	Association of HLA-DQB1*05:02 and DRB1*16 Alleles with Late-Onset, Nonthymomatous, AChR-Ab-Positive Myasthenia Gravis. Autoimmune Diseases, 2012, 2012, 1-3.	2.7	30
38	Periodic acid-Schiff staining on resin muscle sections: Improvement in the histological diagnosis of late-onset Pompe disease. Muscle and Nerve, 2012, 45, 611-612.	1.0	2
39	Aberrant splicing and expression of the non muscle myosin heavy-chain gene MYH14 in DM1 muscle tissues. Neurobiology of Disease, 2012, 45, 264-271.	2.1	20
40	Early subclinical cochlear dysfunction in myotonic dystrophy type 1. European Journal of Neurology, 2011, 18, 1412-1416.	1.7	12
41	Inverse correlation between VEGF and soluble VEGF receptor 2 in POEMS with AIDP responsive to intravenous immunoglobulin. Muscle and Nerve, 2010, 42, 445-448.	1.0	18
42	In AÎ²PPâ€overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AÎ²PP751 and GSK3Î² activation: effects mitigated by lithium and apparently relevant to sporadic inclusionâ€body myositis. Journal of Neurochemistry, 2010, 112, 389-396.	2.1	35
43	The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles. Neuropathology and Applied Neurobiology, 2010, 36, 275-284.	1.8	15
44	Impaired Autophagy in Sporadic Inclusion-Body Myositis and in Endoplasmic Reticulum Stress-Provoked Cultured Human Muscle Fibers. American Journal of Pathology, 2010, 177, 1377-1387.	1.9	94
45	Screening of ARHSP-TCC patients expands the spectrum ofSPG11mutations and includes a large scale gene deletion. Human Mutation, 2009, 30, E500-E519.	1.1	53
46	p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathologica, 2009, 118, 407-413.	3.9	133
47	Late-onset MNGIE without peripheral neuropathy due to incomplete loss of thymidine phosphorylase activity. Neuromuscular Disorders, 2009, 19, 837-840.	0.3	34
48	Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2. Muscle and Nerve, 2008, 38, 1405-1411.	1.0	48
49	In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized. Free Radical Biology and Medicine, 2008, 45, 773-779.	1.3	24
50	Upper motor neuron involvement in X-linked recessive bulbospinal muscular atrophy. Clinical Neurophysiology, 2007, 118, 262-268.	0.7	19
51	Overexpression of ErbB2 and ErbB3 receptors in Schwann cells of patients with Charcotâ€“Marieâ€“Tooth disease type 1A. Muscle and Nerve, 2006, 33, 342-349.	1.0	20
52	Subacute demyelinating polyneuropathy in B-cell lymphoma with IgM antibodies against glycolipid GD1b. Neurological Sciences, 2005, 26, 355-357.	0.9	13